Entera Bio (FRA:5DT) Other Current Liabilities : €0.40 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Entera Bio Other Current Liabilities?

Entera Bio's other current liabilities for the quarter that ended in Mar. 2024 was €0.40 Mil.

Entera Bio's quarterly other current liabilities increased from Sep. 2023 (€0.33 Mil) to Dec. 2023 (€0.34 Mil) and increased from Dec. 2023 (€0.34 Mil) to Mar. 2024 (€0.40 Mil).

Entera Bio's annual other current liabilities declined from Dec. 2021 (€0.40 Mil) to Dec. 2022 (€0.28 Mil) but then increased from Dec. 2022 (€0.28 Mil) to Dec. 2023 (€0.34 Mil).

Entera Bio Other Current Liabilities Historical Data

The historical data trend for Entera Bio's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entera Bio Other Current Liabilities Chart

Entera Bio Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Current Liabilities

Get a 7-Day Free Trial

Entera Bio Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Current Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Entera Bio Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

Entera Bio Other Current Liabilities Related Terms

Thank you for viewing the detailed overview of Entera Bio's Other Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Entera Bio (FRA:5DT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entera Bio Ltd (FRA:5DT) » Definitions » Other Current Liabilities

Comparable Companies

Traded in Other Exchanges

ENTX:USA

Address

Minrav Building - Fifth Floor, Kiryat Hadassah, Jerusalem, ISR, 9112002

Website

https://www.enterabio.com

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

Entera Bio (FRA:5DT) Headlines

No Headlines